

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Jing Tang
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

Jing Tang has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Xuqian Ma
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

| |
|---|
| <p>Xuqian Ma has nothing to disclose.</p> |
|---|

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Xin Chen
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

| |
|--|
| <p>Xin Chen has nothing to disclose.</p> |
|--|

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022

Your Name: Mingqian Feng

Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

Mingqian Feng has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Xin Jin
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

| |
|---|
| <p>Xin Jin has nothing to disclose.</p> |
|---|

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Ke Wang
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

Ke Wang has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Jixi Wan
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

Jixi Wan has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Xianmin Zhu
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| | | | |
| | | | |
| 6 | Payment for expert testimony | _____ None | |
| | | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | _____ None | |
| | | | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| | | | |
| | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| | | | |
| | | | |
| 11 | Stock or stock options | _____ None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| | | | |
| | | | |
| 13 | Other financial or non-financial interests | _____ None | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| |
|--------------------------------------|
| Xianmin Zhu has nothing to disclose. |
|--------------------------------------|

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Rong Xie
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| | | | |
| | | | |
| 6 | Payment for expert testimony | _____ None | |
| | | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | _____ None | |
| | | | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| | | | |
| | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| | | | |
| | | | |
| 11 | Stock or stock options | _____ None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| | | | |
| | | | |
| 13 | Other financial or non-financial interests | _____ None | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

Rong Xie has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022

Your Name: Shuang Dong

Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| | | | |
| | | | |
| 6 | Payment for expert testimony | _____ None | |
| | | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | _____ None | |
| | | | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| | | | |
| | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| | | | |
| | | | |
| 11 | Stock or stock options | _____ None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| | | | |
| | | | |
| 13 | Other financial or non-financial interests | _____ None | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| |
|--------------------------------------|
| Shuang Dong has nothing to disclose. |
|--------------------------------------|

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Sheng Hu
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

Sheng Hu has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Hui Jiang
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

Hui Jiang has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

ICMJE DISCLOSURE FORM

Date: 1-July-2022
 Your Name: Conghua Xie
 Manuscript Title: Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| Time frame: Since the initial planning of the work | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _____ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Time frame: past 36 months | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _____ None | |
| | | | |
| 3 | Royalties or licenses | _____ None | |
| | | | |
| 4 | Consulting fees | _____ None | |
| | | | |

| | | | |
|----|--|------------|--|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _____ None | |
| 6 | Payment for expert testimony | _____ None | |
| 7 | Support for attending meetings and/or travel | _____ None | |
| 8 | Patents planned, issued or pending | _____ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _____ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _____ None | |
| 11 | Stock or stock options | _____ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _____ None | |
| 13 | Other financial or non-financial interests | _____ None | |

Please summarize the above conflict of interest in the following box:

| |
|---|
| <p>Conghua Xie has nothing to disclose.</p> |
|---|

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form. X